ClinicalTrials.gg
CompletedNCT00635401Updated Apr 10, 2008

A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking

A Phase 2 interventional study of Varenicline in Smoking, sponsored by Pfizer. Completed at 8 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-10.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing varenicline in Smoking — none open to participants now, none under way, none of them phase 3. Varenicline · Smoking.

Enrollment
38th of 57
30 · median 83
Started
2004
the only one that year
Phase 2
10 of 57
none open now
Registered
8th of 57
by date
Lead sponsor
3 of 57
Pfizer

Among the 57 studies testing varenicline in Smoking, this one is the 38th largest by enrollment, is the only one that started in 2004, is one of 10 in phase 2, and was the 8th registered.

Smoking

1,513 studies on the registry are indexed under Smoking; 194 are open to participants now.

Browse Smoking studies →

Open to participants now

None of the 57 studies testing varenicline in Smoking is open now. The open studies under Smoking, anywhere →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 140 Smoking studies recruiting now, 74 (53%) set no upper age limit and 48 (34%) stop at 75 or younger; 3 take children under 18; 65 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies testing varenicline in Smoking as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of varenicline in Japanese smokers. Efficacy is evaluated by continuous quit rate and withdrawal symptoms of smokers. Safety is evaluated by adverse events, laboratory tests, and other safety tests.

03

Conditions studied

  • Smoking

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese smokers motivated to quit smoking
  • No period without smoking of more than 3 months
  • Smoked an average of at least 10 cigarettes/day in the past year

Exclusion criteria

Exclusion Criteria:

  • Subjects who have used nicotine replacement therapy within 1 month of the study screening visit
  • Subjects intending to use nicotine replacement therapy or other smoking cessation treatments during the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    0.5 mg BID

    Drug: Varenicline

Interventions

  • 0.5 mg BID for 7 weeks

    Also known as: Chantix, Champix, CP-526,555

06

What researchers measure

Primary outcomes

  1. Carbon monoxide (CO)-confirmed 4-week continuous quit rate (4-week CQR) from Weeks 4 to 7.

    Time frame: Weeks 4-7

Secondary outcomes

  1. CO-confirmed 7-day Point Prevalence from Week 2 through Week 7.

    Time frame: Weeks 2-7

  2. Continuous abstinence rate from target quit date (TQD) from Week 2 through Week 7.

    Time frame: Weeks 2-7

  3. Average number of daily cigarettes smoked from Week 2 through Week 7.

    Time frame: Weeks 2-7

  4. Assessment of withdrawal symptoms by Minnesota Nicotine Withdrawal Scales (MNWS) from Week 2 through Week 7.

    Time frame: Weeks 2-7

  5. Assessment of satisfaction (desirable and aversive effects) obtained from smoking by Smoking Effects Inventory (SEI) (administered only to subjects who had smoked since the previous assessment) from Week 2 through Week 7.

    Time frame: Weeks 2-7

  6. Assessment of tobacco craving by the Brief Questionnaire of Smoking Urges (QSU-Brief) from Week 2 through Week 7.

    Time frame: Weeks 2-7

  7. Assessment of the effect of smoking cessation on subjects' quality of life by the Smoking Cessation Quality of Life (SCQoL) questionnaire from Week 2 through Week 7.

    Time frame: Weeks 2-7

  8. Adverse events, laboratory test changes throughout the study.

    Time frame: Weeks 1-7

07

Study locations

8 sites
  • Pfizer Investigational Site
    Chuo-ku Fukuoka, Fukuoka, Japan
  • Pfizer Investigational Site
    Nishi-ku Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Beppu, Oita, Japan
  • Pfizer Investigational Site
    Hamamatsu-shi, Shizuoka-ken, Japan
  • Pfizer Investigational Site
    Edogawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Toshima-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Oita, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 13, 2008
Start
May 2004
CompletionActual
Aug 2004
Last update
Apr 10, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00635401
Lead sponsor
Pfizer
First posted
Mar 13, 2008
Start date
May 2004
Completion
Aug 2004
Last update
Apr 10, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion